MMP-7 (-181A>G) promoter polymorphisms and risk for cervical cancer

Gynecol Oncol. 2008 Jul;110(1):71-5. doi: 10.1016/j.ygyno.2008.03.007. Epub 2008 May 2.


Objectives: Matrix metalloproteinase (MMP-7) is a secreted matrilysin, which contributes to tumor progression through breakdown of basement membranes and angiogenesis. Therefore, we aimed to investigate the association of MMP-7 -181A>G gene polymorphism with risk of cervical cancer.

Methods: In the present case control study, we enrolled a total of 150 cervical cancer patients confirmed by histopathology and 162 unrelated healthy individuals. Polymorphism for MMP-7 gene (-181A>G) was genotyped by polymerase chain reaction and restriction enzyme length polymorphism.

Results: Frequency of MMP-7 -181GG genotype and -181G allele differed significantly between patients with cervical cancer (29.3%) and healthy individuals (19.4%) (P=0.041; OR(GG)=1.94 and P=0.048; OR(G)=1.94). Individuals with MMP-7 -181GG genotype were at higher risk of stage II of cervical cancer with borderline significance (P=0.05, OR=2.78; 95%CI: 0.89-8.69). However, interaction of MMP-7 -181AG and GG genotypes with tobacco usage did not modulate the cervical cancer risk significantly (OR 2.21, 95%CI=0.59-8.1 and OR 3.17, 95%CI=0.64-15.7).

Conclusion: Individuals with MMP-7 -181GG genotype were at significantly higher risk of cervical cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Genotype
  • Humans
  • Matrix Metalloproteinase 7 / genetics*
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Polymorphism, Genetic*
  • Promoter Regions, Genetic*
  • Risk Factors
  • Smoking / epidemiology
  • Uterine Cervical Neoplasms / epidemiology
  • Uterine Cervical Neoplasms / genetics*
  • Uterine Cervical Neoplasms / pathology


  • Matrix Metalloproteinase 7